scholarly journals The Association of Serum 25-Hydroxyvitamin D and Carcinoembryonic Antigen in Locally Advanced Colorectal Cancer With Neoadjuvant Chemoradiotherapy

2021 ◽  
Author(s):  
Jing Shi ◽  
Yongqi Zhang ◽  
Xiang He ◽  
Hong Ye ◽  
Liping Cheng ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Advanced Colorectal Cancer ◽  
Locally Advanced ◽  
Neoadjuvant Chemoradiotherapy ◽  
Healthy Individuals ◽  
Hydroxyvitamin D ◽  
Locally Advanced Colorectal Cancer ◽  
25 Hydroxyvitamin D ◽  
Serum Cea

Abstract BackgrondWe aimed to describe 25-hydroxyvitamin D [25(OH) D] and carcinoembryonic antigen association levels in patients with locally advanced colorectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (nCRT).MethodsBetween July 2012 and September 2018, the records of 92 stage II/III colorectal cancer patients with treated with nCRT followed by radical surgery were reviewed retrospectively. Enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay was used to analyze the patient’s carcinoembryonic antigen (CEA) and 25(OH) D concentrations in serum.ResultsThe serum levels of 25(OH) D in patients were significantly lower than healthy individuals, just like CEA levels were significantly higher than healthy individuals. The serum CEA in pre-nCRT was significantly lower than in post-nCRT patients, while the serum 25(OH) D from pre-nCRT patients was significantly higher than post-nCRT patients. Our results showed that the pre-nCRT CEA and 25(OH) D level is a risk factor of LARC. ConclusionsNeoadjuvant chemoradiotherapy induces a fall in circulating25(OH) D and carcinoembryonic antigen (CEA). Plasma 25 (OH) D levels is a prognostic biomarker with low 25(OH) D associated with poorer survival. Thus, serum 25(OH) D and CEA levels might be of value in evaluating the pathogenesis and risk of LARC in the future. Moreover, serum CEA or 25(OH) D levels were associated with patient's clinical and pathological features providing data for risk and prognostic prediction.

EXPERIENCE OF THE APPLICATION OF THERMOCHEMIORRADIOTHERAPY IN COMBINED TREATMENT OF DYSTAL CANCER OF DIRECT INTESTINE

2019 ◽  
Vol 65 (1) ◽  
pp. 131-134
Author(s):  
Zhanna Startseva ◽  
Sergey Afanasev ◽  
Dina Plaskeeva
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Primary Tumor ◽  
Advanced Colorectal Cancer ◽  
Combined Treatment ◽  
Locally Advanced ◽  
Chemoradiation Therapy ◽  
Locally Advanced Colorectal Cancer

The article describes the experience of using ther-mochioradiotherapy in the combined treatment of distal locally advanced colorectal cancer, as well as comparing the effectiveness of treatment with chemoradiation therapy. The use of the proposed method as a component of the combined treatment of patients with rectal cancer allowed to increase the percentage of organ-preserving operations. As a result of thermochemotherapy, the prevalence of the primary tumor was significantly reduced, as a result of which the number of sphincter-bearing operations was reduced by almost 2 times (p

Extended resections are beneficial for patients with locally advanced colorectal cancer

1995 ◽  
Vol 38 (12) ◽  
pp. 1251-1256 ◽  
Author(s):  
J. R. Izbicki ◽  
S. B. Hosch ◽  
W. T. Knoefel ◽  
B. Passlick ◽  
C. Bloechle ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Advanced Colorectal Cancer ◽  
Locally Advanced ◽  
Locally Advanced Colorectal Cancer

scholarly journals First-line treatment with modified FOLFOXIRI plus bevacizumab in patients with locally advanced colorectal cancer

2020 ◽  
Vol 28 (1) ◽  
pp. 44-48 ◽  
Author(s):  
Yasufumi Yamada ◽  
Kazuhiko Yoshimatsu ◽  
Hajime Yokomizo ◽  
Sachiyo Okayama ◽  
Hiroyuki Maeda ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Advanced Colorectal Cancer ◽  
Locally Advanced ◽  
Line Treatment ◽  
First Line ◽  
Locally Advanced Colorectal Cancer ◽  
First Line Treatment

Locally advanced colorectal cancer: Is a second look surgery and prophylactic HIPEC warranted?

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15056-e15056 ◽  
Author(s):  
Rahul Bhamre ◽  
Jay Rashmi Anam ◽  
Manish Bhandare ◽  
Avanish Saklani
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
High Risk ◽  
Advanced Colorectal Cancer ◽  
Locally Advanced ◽  
Peritoneal Recurrence ◽  
High Risk Factors ◽  
Second Look ◽  
Locally Advanced Colorectal Cancer

e15056 Background: Peritoneal recurrence/carcinomatosis (PC) after curative surgery for colorectal cancer is the second most common site of recurrence and carries a poor prognosis. PC present relatively in the later stage, are difficult to detect by conventional imaging on follow up, and have limited options to treat after diagnosis. Second look surgery is the only definite option to diagnose early PC and presents an opportunity for disease control by cytoreductive surgery (CRS) and HIPEC. Multiple studies have attempted to identify clinico-pathological risk factors that predict high chances of PC. Our aim is to analyze the recurrence patterns and survival in locally advanced colorectal cancer, in an attempt to identify high risk factors for PC, which can be used as an indication for second look surgery and prophylactic HIPEC in such cases. Methods: Retrospective analysis of a prospectively maintained data of all colorectal cancer patients presenting to a tertiary cancer care referral center in India, from May 2010 to October 2015 was done. All patients who underwent surgery with curative intent and were clinico-pathological stage T4 and/or N2 M0 were included in the analysis. Results: 182 patients underwent curative resection with a clinico-pathological staging of T4 and/or N2 M0. There were 71 recurrences, out of which 30 (42.2%) were peritoneal, 7 (9.9%) were hepatic only while 34 (47.9 %) were non-hepatic systemic or multiple site. For a median follow up of 26 months, the estimated 3 year OS was 78 % while the 3 year DFS was 50.4 %. The median time to diagnosis of peritoneal recurrence was 13 months (4.7 – 55.7). The 3-year OS for patients with peritoneal recurrence was 48.6 % as against 57 % for liver only recurrence and 59.9 % for non liver systemic and multiple site recurrence, with a trend towards poorer survival for peritoneal recurrences, although non-significant (p – 0.377). Conclusions: Locally advanced colorectal cancer has a high risk of peritoneal recurrence which negatively impacts the survival. Well-designed RCTs need to be conducted to identify the high risk factors for PC and whether second look surgery and prophylactic HIPEC in such patients will improve survival with acceptable morbidity and mortality.

Sign in / Sign up

Export Citation Format

Share Document